Compare Remitly Global Inc (RELY) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Remitly Global Inc trades at $24.17 (market cap $4.98B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 11.8× Remitly Global Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| RELY | TAK | |
|---|---|---|
Market Cap | $4.98B | $58.74B |
Volume | 3,501,150 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $26.92 | $19.05 |
52-Week Low | $12.20 | $13.23 |
Typical Hold Time | 53 Days | 1 Days |
Enterprise Value | $4.34B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.675, up 3.25% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats. Revenue surged to $1.64 billion in 2025, with net income turning positive at $67.93 million, reflecting a significant improvement in profitability. Recent news highlights partnerships, such as with Etsy, and strong analyst consensus favoring the stock.
The outlook for RELY is positive, driven by robust revenue growth, expanding margins, and a favorable analyst consensus with a $30.50 price target. Key risks include competitive pressures in fintech and reliance on sustained customer acquisition, but institutional interest and insider holdings suggest confidence in long-term value.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
